Humabs (Switzerland) has gotten some serious recognition for its antibody platform, as its candidates for Influenza have received FDA fast-track designation.

humabs_influenza_medimmune_fda_fast_trackA biologic therapy for Influenza A has been granted Fast Track Designation by the FDA, a ‘programme to accelerate the treatment commercialisation.

The therapy is based on an antibody (MEDI8852) that was initially developed by Humabs. This Biotech used human memory B-cells from patients that recovered from influenza to isolate an antibody with broad influenza-neutralising properties.

ADVERTISEMENT

This idea of studying the immune system of people who overcame the targeted disease is the basis for their drug discovery platform, Cellclone, which allows Humabs to discover antibodies quickly. These antibodies sometimes target previously unknown or multiple mechanisms in infectious diseases.

humabs_cellclone_influenza_hcmv

Top of Humab’s pipeline including the most advanced candidates developed with Cellclone. RSV+MPV are virus responsible for respiratory tract infections (like pneumonia), HCMV stands for human cytomegalovirus, JCV for John Cunningham virus, HSV for herpes simplex. (Source: Humabs)

Besides Influenza, Cellclone was also used to develop antibody therapies for the infamous Ebola and Middle East respiratory syndrome (more commonly known in the news as ‘MERS‘).

MEDI8852 is being developed by MedImmune, the biologics development arm of AstraZeneca. It is currently in phase Ib/IIa trials, after showing acceptable safety levels in a phase I trial

This antibody binds to a highly conserved region of influenza A strain sequences, meaning that it could still be effective with different types of virus (as the virus mutates with time). Therapies becoming ‘outdated’ by quick mutation rates is one of the challenges in developing treatments which tackle influenza.

humabs_cellclone_antibody_influenza_a

Fig 1: Binding areas of antibodies isolated by Humab’s team in the structure of hemagglutinin (HA), a glycoprotein in the membrane of Influenza virus.

The new Fast Track designation should help MedImmune with the future development of this particular drug.

Additionally, it also lends additional credibility to Humab’s platform, which is being used to develop therapies for other infectious diseases, such as pneumonia, hepatitis B and rabies. There are also potential applications in inflammatory diseases and cancers (through immuno-oncological approaches).

FDA’s Fast Track is still not that common for Infectious Disease, so this milestone is great news for both MedImmune and Humabs.


Featured image credit: Remix of Graphics by Labiotech (Source: Humabs)
Figure 1 credit: Xiong et al. (2015) Structures of complexes formed by H5 influenza hemagglutinin with a potent broadly neutralizing human monoclonal antibody, PNAS (doi: 10.1073/pnas.1510816112)
Previous post

French Microbiome Startup Gets €10M to Start Clinical Trials

Next post

Leading German Biotech recruits New talent for Fight against Alzheimer's

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.